Libidon: clinical report reproduced in the Russian institute-report collection (2011)
Comparison in people · 2011
- What was studied
- 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
- Main finding
- In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
Adjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline.
Reported findings and study design
48 men received adjunctive Libidon (28 chronic prostatitis, 20 benign prostatic hyperplasia). Another 22 received usual care. Used uroflowmetry, symptoms and ultrasound.
Population or model 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
Dose, route and schedule
One 10 mg oral capsule twice daily with meals for 30 days alongside usual treatment. The comparator received usual treatment alone.
Protocol source ↗ · Russian institute-report reproduction, methods and Tables 1–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Chronic prostatitis · mean urinary flow | 23.5 vs 19.8 mL/s | Adjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline. |
| Benign prostatic hyperplasia · mean urinary flow | 17.5 vs 14.2 mL/s | Shared baseline column 11.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline. |
| Peak urinary flow | 26.5 vs 24.4 mL/s in prostatitis and 20.5 vs 18.2 mL/s in hyperplasia | Adjunctive Libidon versus usual care. · The report marks neither row as significant relative to baseline. |
| Reported adverse effects | None described | Systematic monitoring and harms by arm are unavailable. |
Tables 2–3 · uroflowmetry
| Measure | Baseline column | Usual care | Usual care + Libidon |
|---|---|---|---|
| Prostatitis · mean flow (mL/s) | 17.3 ± 1.2 | 19.8 ± 1.6 | 23.5 ± 2.4* |
| Prostatitis · peak flow (mL/s) | 22.1 ± 2.3 | 24.4 ± 2.1 | 26.5 ± 3.1 |
| Hyperplasia · mean flow (mL/s) | 11.3 ± 1.2 | 14.2 ± 1.4 | 17.5 ± 1.6* |
| Hyperplasia · peak flow (mL/s) | 16.1 ± 2.3 | 18.2 ± 1.9 | 20.5 ± 2.1 |
Asterisks indicate p < 0.05 versus baseline. The report does not identify the type of ± term.
The tables give a single baseline per diagnostic group and do not state comparator subgroup counts. The significance markers do not test superiority over usual care.
Source for these results ↗ · Reviewed 2026-11-13
Study limitations and source details
Study limitations
- The signed original and protocol have not been authenticated.
- Allocation and blinding are not established; diagnostic subgroups, 22 separately described controls and symptom-specific denominators require reconciliation.
- Concurrent treatment prevents attribution to Libidon alone. No equivalence to Prostatilen or Prostamax is established.
Source details
Institute report — commercial reproduction · Russian PDF brochure
Russian institute-report reproduction, methods and Tables 1–3
Methods and urinary flow tables checked in the Russian reproduction
Sources checked
Citation
Medical Center, St Petersburg Institute of Bioregulation and Gerontology (attributed in reproduction). Libidon: clinical report reproduced in the Russian institute-report collection (2011) Commercial brochure, PDF pages 47–50; institute original unauthenticated